Suicide gene therapy using the herpes simplex virus thymidine kinase/ganciclovir (HSV-tk/GCV) system is a well-characterized tool for cancer gene therapy; however, it does not yet exhibit sufficient efficacy to cure patients of malignancies. We have reported that adenovirally delivered monocyte chemoattractant protein (MCP)-1 augmented the antitumor effects of the HSV-tk/GCV system in an athymic nude mouse model. The current study, which uses an immunocompetent mouse model of colon cancer, was designed to evaluate the antitumor effects of MCP-1 gene delivery in conjunction with this suicide gene therapy system. Subcutaneous tumor foci were directly transduced with both recombinant adenoviruses (rAds) expressing an HSV-tk gene and either of the MCP-1, CD80 and LacZ genes, followed by GCV administration. The growth of tumors was markedly suppressed by codelivery of HSV-tk and MCP-1 genes, which was exclusively associated with the recruitment of monocytes/macrophages, T helper 1 (Th1) cytokine gene expression and cytotoxic activity of the splenocytes. Furthermore, the antitumor effects were more efficient than that obtained by the combination of HSV-tk and CD80 genes. These results suggest an immunomodulatory effect of MCP-1 in the context of suicide gene therapy of colon cancer via orchestration of innate and acquired immune responses.
Introduction
Colon cancer is one of the most common malignant tumors in the world. In its early stages, this disease is usually treated endoscopically, 1 while localized metastatic disease is treated either surgically 2 or by percutaneous ablation therapy. 3 However, advanced colon cancer rarely responds to conventional chemotherapy. 4 Thus, new strategies for the treatment of advanced colon cancer are required.
Over a decade ago, herpes simplex virus-thymidine kinase (HSV-tk) was found to demonstrate tumor cell killing activity in combination with the prodrug ganciclovir (GCV), with this being termed the herpes simplex virus thymidine kinase/ganciclovir (HSV-tk/GCV) suicide gene therapy system. 5 Moreover, nearby unmodified tumor cells are known to be also killed by 'the bystander effect' in this form of therapy. 6, 7 This phenomenon is thought to be due not only to the transfer of toxic GCV metabolites from HSV-tk-modified cells to nontransduced tumor cells through gap junctions, but also to immunemediated antitumor effects via macrophages, T lymphocytes or natural killer (NK) cells. 8, 9 If so, the enhancement of host immune responses, that is, a combination of cytokine gene therapy and the HSV-tk/GCV system, may exert a beneficial effect in eradicating tumor cells.
Monocyte chemoattractant protein (MCP)-1 is a chemokine 10 that regulates the recruitment of monocytes/macrophages to inflammatory sites and tumor tissues as well as their activation, including lysosomal enzyme release and tumoricidal activity, and is functional in both mouse and human. 11 Since MCP-1 has been shown to regulate the chemotatic and tumoricidal effects of monocytes and T lymphocytes in blood, 12, 13 it may be an important mediator of tumor regression. Previous studies indicated that the transfectant-derived MCP-1 successfully recruited monocytes into tumor tissues. 14, 15 We recently proposed a strategy for combination of suicide gene therapy and chemokine gene delivery for the treatment of hepatocellular carcinoma (HCC), based on the data that adenovirally delivered MCP-1 enhanced the antitumor effects of the HSV-tk/GCV system by activating innate immune responses involving monocytes/macrophages. A series of experiments were performed with an athymic nude mouse model of HCC, in which acquired immune responses are deficient. 16, 17 On the other hand, acquired immune responses involving T lymphocytes are known to play an important role in antigen recognition and tumor cytotoxicity. During the process of antigen presentation, MHC complexes holding antigen peptides bind to T-cell antigen receptors with costimulation occurring through CD28-CD80 interactions. 18, 19 In support of this notion, transduction of the CD80 molecule into tumor cells is suggested to induce antitumor immunity in immunocompetent hosts. 20, 21 In the current study, we investigated whether adenovirally delivered MCP-1 gene potentiates the antitumor effects of the HSV-tk/GCV system using an immunocompetent mouse model of colon cancer in comparison with CD80 gene delivery. The results obtained demonstrate that delivery of MCP-1 gene enhances the antitumor effects of the suicide gene system more efficiently than that mediated by transfer of the CD80 gene, presumably by activating both the innate and acquired immune responses.
Materials and methods

Tumor cell lines and cell culture
The mouse colon cancer cell line colon 26 clone 20 22 and mouse HCC cell line BNL 1ME A.7R.1 (BNL), derived from BALB/c mice (H-2 d ), were used for in vitro and in vivo experiments. Cells were cultured in RPMI1640 medium supplemented with 10% heat-inactivated fetal bovine serum (FBS), nonessential amino acids, sodium pyruvate, 2-mercaptoethanol, HEPES buffer, 2 mM glutamate, 1 mM penicillin/streptomycin, and 0.2 mM gentamicin (Gibco, Long Island, NY).
Recombinant adenoviral vectors
The following replication-defective adenoviral vectors, driven by the CAG (C: cytomegarovirus enhancer, A: chicken beta-actin promoter, G: rabbit beta-globin polyA) promoter, 23 were prepared by recombinant DNA technology: Ad-tk (which expressed the HSV-tk gene), Ad-CD80 (which expressed the CD80 gene), Ad-MCP-1 (which expressed the MCP-1 gene), and Ad-LacZ (which expressed the LacZ gene) (Figure 1) . 16, 17 Each adenoviral type was purified and titrated according to protocols supplied by the manufacturer (Takara, Ootsu, Japan). Briefly, each gene fragment, that is HSV-tk, CD80, MCP-1 and LacZ, was excised from respective insert-containing pBluescript vectors. In each case, the resultant fragment was inserted into the pAxCA-wt cosmid (Takara, Ootsu, Japan), which contains essentially the full-length adenovirus type 5 genome apart from E1 and E3 regions (thus, generating the pAxCA gene). Eventually, recombinant adenovirus (rAd) was generated by transfecting 293 cells with the pAxCA-gene and adenovirus 5-dIX DNA-terminal protein complex. 24 These rAds were propagated in 293 cells as previously described. 25 Viral stocks were prepared by the standard protocol. 26 The titer of rAd was determined by the 50% tissue culture infectious dose (TCID 50 ) method. Enzyme-linked immunosorbent assay (ELISA) for MCP-1 expression Aliquots of 1 Â 10 6 colon 26 clone 20 cells were seeded in 3 ml of culture medium in a six-well tissue culture plate. After 24 h, the cells were infected with rAd by MOI 50. After 48 h, 2 ml of culture medium was collected from the infected cell culture. The concentration of MCP-1 in this medium was determined by ELISA as described previously. 28 Briefly, each well of a 96-well microtiter plate (Nalgene, Rochester, NY) was coated with 0.05 M carbonate buffer (pH 9.6) containing monoclonal anti-human MCP-1 antibody (ME61; 1 mg/ml) overnight at 41C After washing with PBS containing 0.05% Tween-20 (PBS-T), the plates were blocked with PBS containing 1% BSA for 1 h at 371C and washed. Subsequently, diluted culture medium or varying concentrations of recombinant MCP-1 were added to duplicate wells and incubated for 2 h at 371C Following incubation, the plates were washed and incubated first with rabbit anti-MCP-1 antibodies (1 mg/ml), followed by alkaline phosphataseconjugated goat anti-rabbit antibody (1/12 000; Tago, Burlingame, CA), each for 2 h at 371C. After the plate was washed, aliquots of 1 mg/ml p-nitrophenylphosphate (Sigma, St Louis, MO) in 1 M diethanolamine (pH 9.8) supplemented with 0.5 mM MgCl 2 were added to the wells and the plate was incubated for 40 min at room temperature. After addition of 1 M NaOH, the optical density (405 nm wavelength-OD 405 ) was assessed using an ELISA plate reader (MTP-120; Corona Electric, Ibaragi, Japan). Data were derived from independent, triplicate observations.
In vitro GCV sensitivity
The sensitivity of rAd-infected cells to GCV was determined using a nonradioactive cell proliferation assay, according to the manufacturer's protocol (MTS assay, cellTiter 96 Non-radioactive cell proliferation assay; Promega, Madison, WI). Briefly, 1 Â 10 5 colon 26 clone 20 cells were seeded on each well of six-well plate. After 24 h incubation, cells were infected with rAds by MOI 50. At 48 h, 5 Â 10 3 cells were aliquoted into wells of a 96-well plate. After 24 h, GCV (Tanabe Pharmaceutical Drug, Tokyo, Japan) was added in increasing concentrations (0, 0.1, 1, 10 mg/ml). After 48 h incubation, the percentage of surviving cells was calculated as a percentage of absorbance found in the GCV-treated cells divided by that found in the cells without GCV treatment (mean7s.d.).
Animal experiments
Male mice (8 weeks old) (BALB/cA Jcl, CLEA Japan) (H-2 d ) were subcutaneously injected with the indicated numbers of colon 26 clone 20 cells on day 1. On days 2 and 3, 3 Â 10 7 TCID 50 (50 ml) of each rAd or PBS (À) was injected into the tumor foci. Virus mixtures and single vector were composed with each 3 Â 10 7 TCID 50 in 50 ml, so total volumes were 100 ml and ratios of viruses were 1:1. Subsequently, 75 mg/body of GCV was then administered into the peritoneal cavity daily over 5 consecutive days (days 4-8). Tumor size was measured every 7 days and tumor volume was calculated using the following equation: (the longest diameter) Â (the shortest diameter). For histopathological analysis, tumor tissues were fixed in 10% zinc-buffered formalin, embedded in paraffin, sectioned at 2 mm thickness and stained with hematoxylin and eosin. Data were derived from independent, duplicate observations. Animal experiments were conducted in accordance with institutional guidelines.
Immunohistochemical analysis
Tumor tissues resected on day 8 were embedded in OCT compound (Sakura Finetek, Torrance, CA) and snapfrozen in liquid nitrogen. Cryostat sections of frozen tissues were fixed in cold acetone for 10 min, followed by three rinses in PBS to stain with anti-Mac-1 (CD11b) and fixed with PLPD methods to stain with anti-CD4 and anti-CD8. 29 To avoid nonspecific staining, avidin and biotin in the tissues were blocked using a blocking kit (Vector Laboratories, Burlingame, CA). The slides were incubated with each antibody for 30 min at room temperature. Biotin-conjugated rat IgG 2b , k was used as the negative control. The reaction was visualized by using the VECTASTAIN ABC Standard Kit (Vector Laboratories), followed by counterstaining with hematoxylin. Serial sections were fixed in 10% zinc-buffered formalin and stained with hematoxylin and eosin.
Reverse transcriptional polymerase chain reaction (RT-PCR) analysis for cytokine gene expression Total RNA was extracted from tumor tissues resected on day 8 using a ToTALLY RNA kit (Ambion, Austin, TX), according to the manufacturer's protocols. Briefly, RT-PCR analysis was performed with 1 mg of total RNA and an Oligo dT-Adaptor Primer, by using an RNA PCR kit (AMV) Ver.2.1 (Takara, Ootsu, Japan). PCR amplification was run for 2 min at 941C, followed by 30 cycles of 30 s at 941C, 30 s at 561C and 90 s at 721C. PCR primers used in this reaction are indicated as follows: CTL analysis ( 51 Cr release assay) Cytolytic activity of mouse spleen cells were assessed by a 51 Cr-labeled release assay, as previously described. 30 Briefly, each treated mouse was sacrificed on day 8. Splenocytes were harvested aseptically and mashed in alpha-MEM medium (Gibco) with 10% FBS and a single spleen cell suspension was prepared. Spleen cells were cultured with mitomycin C (MMC, Sigma) (400 mg/4 ml, 
Statistical analysis
Results are expressed as means7s.e. Differences between groups were analyzed for statistical significance by the repeated measure ANOVA test. A P-value of o0.05 was considered statistically significant. 
Results
CD80 expression of rAds
MCP-1 production of rAds
To measure the production of MCP-1 by the rAd vectors, colon 26 clone 20 cells were infected with the vectors, and the concentrations in the medium were quantitated by ELISA (Figure 3) . Colon 26 clone 20 cells infected with Ad-MCP-1 or with Ad-tk þ Ad-MCP-1 secreted MCP-1 at levels of 6.171.5 and 7.072.3 ng/ml, respectively. However, MCP-1 concentration from culture supernatants was o0.001 ng/ml in noninfected colon 26 clone 20 cells, as well as Ad-LacZ infected cells, Ad-tk þ Ad-CD80 infected cells, and Ad-tk þ Ad-LacZ infected cells. The results demonstrate that large amounts of MCP-1 were produced by the rAd harboring the MCP-1 gene, and that the production was not influenced by coinfection with the rAd expressing HSV-tk. In addition, the functional properties of MCP-1 produced by this rAd were defined previously. 16 
Tumoricidal activity of rAds with GCV treatment in vitro
To compare the tumoricidal activities of the HSV-tk/ GCV system when infected with the rAds, colon 26 clone 20 cells were infected with Ad-tk, as well as the rAds expressing CD80, MCP-1 and LacZ treated with GCV, and the resulting survival rates of infected cells monitored by MTS assay (Figure 4 ). The percentage of viable 
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T Kagaya et al noninfected colon 26 clone 20 cells was almost 100%, even with varying concentrations of GCV. In cells infected with Ad-tk, cell viability decreased in correlation with elevation in GCV concentrations. These data indicate that the tumoricidal activity of the rAd expressing HSV-tk was not affected by coinfection of the rAds used in this study. 
Antitumor effects of rAds with GCV treatment in vivo
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Recruitment of immune cells in tumor foci
To understand the involvement of immune responses in enhancement of the antitumor effects of the rAd expressing HSV-tk by codelivery of CD80 and MCP-1, the recruitment of CD4 þ , CD8 þ T lymphocytes and Mac-1 þ monocytes/macrophages was evaluated immunohistochemically via the use of specific monoclonal antibodies. As shown in Figure 7 , in the Ad-tk þ Ad-CD80 group, most of the infiltrating mononuclear cells observed in the tumor foci were positive for CD4 and CD8, not Mac-1. In contrast, marked infiltration of Mac-1 þ cells was seen in the Ad-tk þ Ad-MCP-1 group. On the other, in Ad-LacZ þ Ad-CD80 and in Ad-LacZ þ Ad-MCP-1, immune cells were not recruited in the tumor tissues. In the previous studies, we confirmed that no apoptosis was induced in HSV-tk delivered cells and no recruitment of immune cells occurred without GCV treatment. 16 These data indicate that the enhancement Figure 7 Immunohistochemical analysis of colon 26 clone 20 tumors infected with rAds. In the experiment described in the legend to Figure 6 , tumors were resected on day 8 and analyzed immunohistochemically. Tumor tissues treated with Ad-LacZ þ Ad-CD80 or Ad-LacZ þ Ad-MCP-1 or Ad-tk þ Ad-CD80 or with Ad-tk þ Ad-MCP-1 or with Ad-tk þ Ad-LacZ were stained with hematoxylin and eosin (H-E). The same tumor tissues were stained with anti-Mac-1 antibody, as well as anti-CD4 and anti-CD8 antibodies. Original magnification, Â 400. On days 2 and 3, 3 Â 10 7 TCID 50 of rAds were injected into the tumor foci. Subsequently, 75 mg/kg of GCV was administered for five consecutive days (days 4-8). Tumor sizes were measured every 7 days. *Po0.05 and **Po0.01 when compared to Ad-tk þ Ad-LacZ.
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T Kagaya et al of the antitumor effects of the suicide gene HSV-tk mediated by CD80 was associated with a remarkable recruitment of CD4 þ and CD8 þ T lymphocytes, and that mediated by MCP-1 was associated with a great infiltration of Mac-1 þ monocytes/macrophages. These results suggest that the antitumor activities of CD80 and MCP-1 may be mediated by differential immune mechanisms in this mouse model of colon cancer.
Cytokine gene expression in tumor foci
The activated state of tumor infiltrating immune cells following infection with the rAds was analyzed by semiquantitatively measuring expression of several cytokines, namely IL-4, TNF-a, IFN-g and IL-12p40, at the mRNA level by RT-PCR analysis (Figure 8 ). IL-4 and IL-12p40 were not induced in samples derived from any of the groups. TNF-a and IFN-g were induced in Ad-tk þ Ad-LacZ, Ad-tk þ Ad-CD80 and Ad-tk þ Ad-MCP-1 groups. These data suggest that tumor infiltrating T lymphocytes and monocytes/macrophages were activated to enhance tumor immunity.
Cytotoxic activities of splenocytes
To evaluate the cytotoxic activities of immune cells derived from mice treated with the rAds, isolated and pulsed splenocytes were incubated with 51 Cr-labeled colon 26 clone 20 cells in a standard 4 h cytotoxicity assay. In the Ad-tk þ Ad-CD80 and Ad-tk þ Ad-MCP-1 groups, cytotoxic T lymphocytes (CTLs) specific for colon 26 clone 20 cells were induced in contrast to the Ad-tk þ Ad-LacZ group (Figure 9 ). These results indicate that cytotoxic activity was induced by codelivery of a suicide gene and CD80 or MCP-1, corresponding to their enhancement of the antitumor effects in vivo.
Discussion
The suicide gene system is a well-characterized tool for cancer gene therapy. However, its efficacy is not sufficient to cure the patients of the malignancies. Some new strategies have been proposed to enhance the antitumor effects of suicide gene therapy, that is, by induction of immune responses to tumor cells via coexpression of cytokine and chemokine genes. Recent studies have demonstrated that codelivery strategies employing IL-2 and HSV-tk, 31 IL-2, GM-CSF and HSV-tk, 32 IL-12 and HSV-tk, 33 IL-4 and HSV-tk, 34 TNF-a and HSV-tk, 35 as well as IFN-a2a and HSV-tk 36 are relatively effective compared to treatment with the suicide gene alone.
We have previously proposed a strategy to augment the efficacy of suicide gene-based therapy for cancer cells by using the combined heterochronic administration of Effects of MCP-1 and HSV-tk on colon cancer T Kagaya et al HSV-tk and MCP-1 genes, 16 and bicistronic delivery of HSV-tk and MCP-1 genes 17 in an athymic nude mouse model of HCC. The current study demonstrated that codelivery of HSV-tk and MCP-1 genes greatly enhanced antitumor effects in an immunocompetent mouse model of colon cancer, which were stronger than the combination of HSV-tk and CD80. The antitumor responses due to HSV-tk and MCP-1 gene delivery were associated with the recruitment of monocytes/macrophages, T helper 1 (Th1) cytokine gene expression and cytotoxic activity of the splenocytes. These results suggest that the immunomodulatory effects of MCP-1 may contribute to the development of a new strategy based on the suicide gene therapy of colon cancer.
Recent reports demonstrated that monocyte recruitment was dependent on the level of MCP-1 secreted by the tumor cells and that antitumor effects were correlated to the extent of their infiltration. 14, 15, 37, 38 In support of this notion, the proportion of macrophages in tumor tissue was increased following delivery of the MCP-1 gene in contrast to treatment with the CD80 gene, suggesting that MCP-1 expression in the tumor may contribute to the induction of antitumor effects by recruiting monocytes/macrophages in this mouse model of colon cancer. Furthermore, the antitumor effects of Ad-MCP-1 were correlated with TNF-a production, presumably secreted by the recruited macrophages. Consistent with the observations, we have reported that when macrophages were exposed to apoptotic tumor cells, their production of TNF-a, a tumoricidal cytokine, 39 was markedly increased. 16 Collectively, the antitumor effects in this suicide gene and chemokine system may be due to the synergistic effects of the recruitment of monocytes/ macrophages by MCP-1 gene expression in the tumor tissues and the induction of TNF-a following their recognition of apoptotic tumor cells arising from use of the HSV-tk/GCV system. We demonstrated that a combination of two rAd vectors, namely Ad-tk and Ad-MCP-1, suppressed tumor growth more efficiently than Ad-tk alone or a combination with Ad-tk and Ad-CD80. CD80 is a costimulatory molecule expressed on antigen-presenting cells (APCs) that plays an integral role in activating T lymphocytes in the process of antigen presentation by the MHC complex to T cell antigen receptor. 40, 41 Expression of CD80 was reported to be decreased in the HCC cell lines, 42 and when CD80 was expressed adenovirally, tumor growth was significantly suppressed. 43 However, this effect was fairly weak, so codelivery of CD80 and IL-12 was proposed to enhance antitumor immunity. 43 Furthermore, codelivery of CD80 and HSV-tk was implicated by using adenoassociated virus vector. 44 Interestingly, these data indicate the delivery of the MCP-1 gene induced similar levels of CTL activity in the splenocytes comparable to that observed with the CD80 gene, in which the antigen presentation may be promoted by the recruited macrophages. More importantly, the current results suggest that the combination of the HSV-tk/GCV system with the MCP-1 gene may be more effective in induction of antitumor effects than that attainable with the CD80 gene, presumably due to the combined effects of the induction of CTL activity and the production of TNF-a by the recruited macrophages.
Although the data presented here appear to be promising, a number of problems remain to be solved before clinical application. First, subcutaneous tumor models of a colon cancer cell line may not be relevant to colon cancers in patients. However, in cases of nonsurgical procedures for liver metastasis of colon cancer, such as percutaneous radiofrequent ablation therapy and transcatheter arterial chemotherapy, 45 administration of the current rAd vectors could be easily applicable to ensure tumor cell killing. In support of this notion, intrahepatic arterial injection of CMV-tk/ GCV system led to a significant antitumoral effect in small tumor nodules. 46 Second, if this model applied to the intra-arterial procedure, rAd might elicit its immunogenicity or cytotoxity, especially when spread via blood flow. The recently used high-dose rAds caused severe unexpected side effects. 47 Although the problems of rAd vectors need to be resolved for clinical application, the current study suggests the possibility of a new strategy of immune gene therapy accompanied by a suicide gene system in treating colon cancer and tumors of other lineages.
